NantKwest, Inc, a clinical-stage immunotherapy company, develops immunotherapeutic treatments for cancer and viral infectious diseases in the United States. The company develops activated natural killer (aNK) cell, a natural killer cell-line and genetically modified derivative capable of killing cancer and virally infected cells; and NANT cancer vaccine, a personalized therapy that utilizes its off-the-shelf natural killer cells.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone858-633-0300
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$50,000.00
Profitability
Miscellaneous
Employees161
Next Earnings Date8/14/2019 (Estimated)
OptionableOptionable
Nantkwest (NASDAQ:NK) Frequently Asked Questions
What is Nantkwest's stock symbol?
Nantkwest trades on the NASDAQ under the ticker symbol "NK."
How were Nantkwest's earnings last quarter?
Nantkwest Inc (NASDAQ:NK) released its quarterly earnings results on Monday, August, 15th. The biotechnology company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. The biotechnology company earned $0.01 million during the quarter, compared to the consensus estimate of $0.10 million. Nantkwest had a negative net margin of 184,234.05% and a negative return on equity of 52.68%. View Nantkwest's Earnings History.
When is Nantkwest's next earnings date?
What price target have analysts set for NK?
2 equities research analysts have issued 12 month price targets for Nantkwest's stock. Their forecasts range from $1.00 to $3.50. On average, they expect Nantkwest's stock price to reach $2.25 in the next year. This suggests a possible upside of 104.5% from the stock's current price. View Analyst Price Targets for Nantkwest.
What is the consensus analysts' recommendation for Nantkwest?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nantkwest in the last year. There are currently 1 sell rating and 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nantkwest.
Has Nantkwest been receiving favorable news coverage?
News coverage about NK stock has trended somewhat negative recently, according to InfoTrie Sentiment Analysis. The research group rates the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Nantkwest earned a coverage optimism score of -1.0 on InfoTrie's scale. They also assigned media stories about the biotechnology company a news buzz of 9.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the near term. View News Stories for Nantkwest.
Who are some of Nantkwest's key competitors?
Some companies that are related to Nantkwest include Krystal Biotech (KRYS), Replimune Group (REPL), BioCryst Pharmaceuticals (BCRX), BioCardia (BCDA), Agenus (AGEN), Gritstone Oncology (GRTS), Tcr2 Therapeutics (TCRR), Acorda Therapeutics (ACOR), Adaptimmune Therapeutics (ADAP), PDL BioPharma (PDLI), LogicBio Therapeutics (LOGC), Avrobio (AVRO), CASI Pharmaceuticals (CASI), Harpoon Therapeutics (HARP) and Sutro Biopharma (STRO).
What other stocks do shareholders of Nantkwest own?
Who are Nantkwest's key executives?
Nantkwest's management team includes the folowing people:
- Dr. Patrick Soon-Shiong F.A.C.S., FRCS (C), M.D., FACS, Exec. Chairman & CEO (Age 66)
- Dr. Barry J. Simon, Pres, Chief Admin. Officer & Exec. Director (Age 54)
- Mr. Richard J. Tajak, Consultant (Age 66)
- Ms. Sonja Nelson, CFO & Principal Financial Officer (Age 46)
- Mr. David J. Pyrce, Chief Commercial Officer and Sr. VP of Innovation & Investor Relations (Age 62)
When did Nantkwest IPO?
(NK) raised $150 million in an IPO on Tuesday, July 28th 2015. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. BofA Merrill Lynch, Citigroup, Jefferies and Piper Jaffray acted as the underwriters for the IPO and MLV & Co. was co-manager.
Who are Nantkwest's major shareholders?
Which major investors are buying Nantkwest stock?
How do I buy shares of Nantkwest?
Shares of NK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nantkwest's stock price today?
One share of NK stock can currently be purchased for approximately $1.10.
How big of a company is Nantkwest?
Nantkwest has a market capitalization of $108.54 million and generates $50,000.00 in revenue each year. The biotechnology company earns $-96,230,000.00 in net income (profit) each year or ($1.22) on an earnings per share basis. Nantkwest employs 161 workers across the globe.View Additional Information About Nantkwest.
What is Nantkwest's official website?
How can I contact Nantkwest?
Nantkwest's mailing address is 3530 JOHN HOPKINS COURT, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-633-0300 or via email at [email protected]
MarketBeat Community Rating for Nantkwest (NASDAQ NK)
MarketBeat's community ratings are surveys of what our community members think about Nantkwest and other stocks. Vote "Outperform" if you believe NK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NK will underperform the S&P 500 over the long term. You may vote once every thirty days.
